Gangliosides from human melanoma immunomodulate response of T cells to interleukin-2.
The gangliosides expressed by normal melanocytes are predominantly GM3 (greater than 90%) and GD3 (less than 5%). Malignant melanoma can express several other types of gangliosides in significant quantities, including GM2 and GD2. Melanoma patients can develop an immune response against some of these ganglioside antigens on autologous melanoma cells. The four major gangliosides expressed by human melanoma cells (GM3, GD3, GM2, and GD2) were examined for their immunomodulatory effect on lymph node lymphocytes from melanoma patients. Gangliosides were added exogenously to lymphocytes grown in the presence of IL-2. Preferential interactions of specific melanoma gangliosides on IL-2 stimulation were found. While GM2 and GD2 enhanced the lymphocyte response to IL-2, GM3 and GD3 significantly inhibited this response. GM2 and GD2 differ from GM3 and GD3 by the presence of a terminal N-acetylgalactosamine. Since different gangliosides can up-regulate and down-regulate lymphocyte responses to IL-2, the ganglioside phenotype of melanoma cells may play a major role in determining whether an individual tumor causes immune stimulation or suppression.
D002470:Cell Survival / Q000187:drug effects; D002478:Cells, Cultured; D005732:Gangliosides / Q000494:pharmacology* / Q000633:toxicity; D006801:Humans; D007376:Interleukin-2 / Q000494:pharmacology*; D008213:Lymphocyte Activation / Q000187:drug effects*; D008545:Melanoma / Q000032:analysis / Q000276:immunology*; D011485:Protein Binding; D011971:Receptors, Immunologic / Q000187:drug effects; D015375:Receptors, Interleukin-2
D005732:Gangliosides; D007376:Interleukin-2; D011971:Receptors, Immunologic; D015375:Receptors, Interleukin-2